← Leaderboards
David Rotella
Rbhs-New Jersey Medical School
$1,892,526
Attributed
$5,677,579
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $737.8K · FY2017–24$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,677,579 · 2
By mechanism
R01$5,677,579 · 2
Top collaborators
- Charles S. Hoffman5 shared
- Michy Patrice Kelly5 shared
- Purnima Bhanot3 shared
- John Joseph Siekierka3 shared
Most similar at Rbhs-New Jersey Medical School
Same institution · by research overlap
- John Joseph Siekierka$705,905
Others in their field
Other Emerging Leaders on “Drug Targeting”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Susan Abushakra · Alzheon, Inc.$47,265,244
- John Damon Chodera · Sloan-Kettering Inst Can Research$38,850,978
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
Research focus
Drug TargetingGenesEvaluationScreeningCellsIn VivoIn VitroGeneticMouse ModelPreventAnalogOralAnimalsLeadEnzymesDoseSide EffectAnteriorAdverse EventAnimal ModelBaseAge RelatedBehavioral StudyAged
Grant awards (8)
Pharmacologic Inhibition of PDE11A for Age-Related Memory Disorders$678,484
R01 · FY2024 · AG · contact PI
Pharmacologic Inhibition of PDE11A for Age-Related Memory Disorders$726,045
R01 · FY2023 · AG · contact PI
Pharmacologic Inhibition of PDE11A for Age-Related Memory Disorders$731,471
R01 · FY2022 · AG · contact PI
Pharmacologic Inhibition of PDE11A for Age-Related Memory Disorders$737,807
R01 · FY2021 · AG · contact PI
Pharmacologic Inhibition of PDE11A for Age-Related Memory Disorders$686,057
R01 · FY2020 · AG · contact PI
Development of inhibitors of P. falciparum cGMP dependent protein kinase (PfPKG) for malaria chemoprevention$694,721
R01 · FY2019 · AI
Development of inhibitors of P. falciparum cGMP dependent protein kinase (PfPKG) for malaria chemoprevention$701,820
R01 · FY2018 · AI
Development of inhibitors of P. falciparum cGMP dependent protein kinase (PfPKG) for malaria chemoprevention$721,174
R01 · FY2017 · AI